| Missing novelty in drug development J Krieger, D Li, D Papanikolaou The Review of Financial Studies 35 (2), 636-679, 2022 | 193* | 2022 |
| Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse A Braun, S Zhang, HE Miettinen, S Ebrahim, TM Holm, E Vasile, MJ Post, ... Proceedings of the National Academy of Sciences 100 (12), 7283-7288, 2003 | 181 | 2003 |
| The career effects of scandal: Evidence from scientific retractions P Azoulay, A Bonatti, JL Krieger Research Policy 46 (9), 1552-1569, 2017 | 158 | 2017 |
| Retractions P Azoulay, JL Furman, JL Krieger, F Murray Review of Economics and Statistics 97 (5), 1118-1136, 2015 | 150 | 2015 |
| Trials and terminations: Learning from competitors’ R&D failures JL Krieger Management Science 67 (9), 5525-5548, 2021 | 141 | 2021 |
| Standing on the shoulders of science JL Krieger, M Schnitzer, M Watzinger Strategic Management Journal 45 (9), 1670-1695, 2024 | 61* | 2024 |
| Find and replace: R&D investment following the erosion of existing products JL Krieger, X Li, RT Thakor Management Science 68 (9), 6552-6571, 2022 | 51 | 2022 |
| Old moats for new models: Openness, control, and competition in generative ai P Azoulay, JL Krieger, A Nagaraj National Bureau of Economic Research, 2024 | 33 | 2024 |
| The impact of personal genomics on risk perceptions and medical decision-making JL Krieger, F Murray, JS Roberts, RC Green Nature Biotechnology 34 (9), 912-918, 2016 | 31 | 2016 |
| Private and social returns to R&D: drug development and demographics E Benmelech, J Eberly, D Papanikolaou, J Krieger AEA Papers and Proceedings 111, 336-340, 2021 | 16 | 2021 |
| Evaluation and Learning in R&D Investment AP Frankel, JL Krieger, D Li, D Papanikolaou National Bureau of Economic Research, 2023 | 6 | 2023 |
| Are Transformational Ideas Harder to Fund? Resource Allocation to R&D Projects at a Global Pharmaceutical Firm J Krieger, R Nanda | 6 | 2022 |
| Missing novelty in drug development (No. w24595) JL Krieger, D Li, D Papanikolaou National Bureau of Economic Research, 2018 | 5 | 2018 |
| How Important is Editorial Gatekeeping? Evidence from Top Biomedical Journals JL Krieger, KR Myers, AD Stern The Review of Economics and Statistics, 1-33, 2023 | 4* | 2023 |
| Dusting off the old ones: Drug licensing to startups, innovation success and efficiency M Hammoudeh, J Krieger, J Xu SSRN, 2022 | 3 | 2022 |
| Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices J Shafrin, J Kim, JT Cohen, LP Garrison, DA Goldman, JA Doshi, J Krieger, ... Forum for Health Economics and Policy 27 (1), 29-116, 2024 | 1 | 2024 |
| HTA75 Prioritized attributes to better define and measure innovation in health technology assessment: findings from an expert roundtable R Xie, MY Cheng, J Bright, J Spangler, JL Krieger, M Graglia, R Chapman Value in Health 26 (6), S273, 2023 | 1 | 2023 |
| Old Moats for New Models: Openness, Control, and Competition in Generative Artificial Intelligence P Azoulay, J Krieger, A Nagaraj Entrepreneurship and Innovation Policy and the Economy 4 (1), 7-46, 2025 | | 2025 |
| Charting (and Updating) the Path: A Bayesian Perspective on Entrepreneurial Learning JL Krieger Harvard Business School, 2024 | | 2024 |
| Forum for health economics & policy: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices J Shafrin, J Kim, JT Cohen, LP Garrison, DA Goldman, JA Doshi, J Krieger, ... De Gruyter, 2024 | | 2024 |
Pierre AzoulayProfessor, MITZweryfikowany adres z mit.edu